(0)
- Purchase now
- Products
- Activity
- About
- Nutritionist
- Award
- Social Responsibility
A new in vitro study shows the ability of ColdZyme to deactivate novel coronavirus |
| Date：2022-02-16 |
|
Enzymatica announces (21 Feb 2020) the preliminary results of an in vitro study showing the ability of the mouth spray ColdZyme® to deactivate novel virus, the virus causing the pandemic. The study demonstrated that ColdZyme deactivates novel virus by 98.3% (1.76 log10). The results indicate that ColdZyme can offer a protective barrier against harmful viruses such as novel virus by local virus deactivation in the oral cavity.
The medical device ColdZyme is a mouth spray that forms a barrier in the oral cavity against common cold viruses. The barrier solution of the device is mainly composed of glycerol and Atlantic cod trypsin. The goal of the present study was to determine the ability of ColdZyme to deactivate novel virus known to cause the pandemic. A virucidal efficacy suspension test was conducted using ColdZyme against novel virus. ColdZyme deactivated novel virus by 98.3% (1.76 log10) in 20 minutes. Furthermore, no cytotoxicity was detected for ColdZyme at any dilution tested. The study was conducted by the US company Microbac Laboratories Inc - an independent, accredited and certified laboratory.
The in vitro study was based on a standardized and validated methodology, i.e. ASTM International test method designated E1052 “Standard Test Method to Assess the Activity of Microbicides against Viruses in Suspension”.
Previous in vitro results made with the same method showed that ColdZyme is effective against another virus, one of the causes of the common cold, and in comparison to novel virus belongs to another subgroup within the its family. The aggregated results indicate that ColdZyme can be effective against novel virus & virus which causes the common cold.
Novel virus actively replicates in the throat and shows high viral shedding also at a time of mild symptoms. Therefore, ColdZyme sprayed onto the mouth and throat could lower the risk of infection, and decrease the viral load locally. Lowered viral load may decrease viral shedding and thus minimize the spread of novel virus.
"Even if the current in vitro results cannot be directly translated into clinical efficacy, it is very interesting that ColdZyme is able to effectively deactivate novel virus in vitro since it constitutes a proof-of-principle that can be taken further into clinical studies. Thus, the results indicate that ColdZyme can offer a protective barrier against novel virus," says Claus Egstrand, Enzymatica's Chief Operating Officer.
*This Press release was revised according to Hong Kong Undesirable Medical Advertisements Ordinance
For more information, please visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases
Source:https://bit.ly/30IzXnz
|
We use cookies
